Overview A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM) Status: Recruiting Trial end date: 2021-12-01 Target enrollment: Participant gender: Summary An open-label, ascending dose study for adult patients with inclusion body myositis (IBM). Phase: Phase 1 Details Lead Sponsor: Abcuro, Inc.